<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801905</url>
  </required_header>
  <id_info>
    <org_study_id>NEPAFENAC IN PRFC</org_study_id>
    <secondary_id>NEPAFENACO</secondary_id>
    <nct_id>NCT00801905</nct_id>
  </id_info>
  <brief_title>Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation</brief_title>
  <acronym>NEPAF</acronym>
  <official_title>Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether topical nepafenac (qid) is effective in&#xD;
      preventing and treating macular thickening related pan-retinal photocoagulation in patients&#xD;
      with diabetic retinopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To evaluate the effect of topical nepafenac 0.1 %, in preventing and in treating&#xD;
      macular thickening related to pan-retinal photocoagulation in diabetic patients. Material and&#xD;
      methods: This is a prospective, longitudinal, and controlled study in patients with diabetic&#xD;
      retinopathy (severe non-proliferative and proliferative retinopathy), with a symmetric&#xD;
      severity in both eyes and without a clinical significant macular edema. The best corrected&#xD;
      visual acuity (BCVA) in all patients was 20/80 or better. All patients will undergo&#xD;
      pan-retinal photocoagulation in three different sessions (with 2 weeks in apart between&#xD;
      them). Each patient will receive topical nepafenac 0.1% (qid) on one eye, and placebo (qid)&#xD;
      at the fellow eye, starting 1 week before the first retinal photocoagulation session and&#xD;
      continued for 9 weeks ( ending 4 weeks after pan-retinal photocoagulation is completed).&#xD;
      Spectral domain OCT and BCVA in ETDRS scale will be performed before and at 2 weeks after&#xD;
      each laser session, and at 1, 2 and 3 months after treatment completed. BCVA and OCT outcomes&#xD;
      of each studied period will be compared on both eyes, and side effects will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">March 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central macular thickening</measure>
    <time_frame>2 weeks after each laser session and 1 and 2 months after last laser session</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>2 weeks after each laser session, 1, 2 and 3 months after pan-retinal photocoagulation is completed</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Macular Thickening</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>1: Nepafenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac</intervention_name>
    <description>Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.</description>
    <arm_group_label>1: Nepafenac</arm_group_label>
    <other_name>Nevanac 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lubricant</intervention_name>
    <description>Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed</description>
    <arm_group_label>2: placebo</arm_group_label>
    <other_name>Systane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Severe and proliferative Diabetic Retinopathy&#xD;
&#xD;
          -  Symmetric severity grade on both eyes&#xD;
&#xD;
          -  Best corrected visual acuity better than 20/80&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical significant macular edema&#xD;
&#xD;
          -  Lens opacity&#xD;
&#xD;
          -  Ocular surgery 6 months or less before recruit&#xD;
&#xD;
          -  Uveitis history&#xD;
&#xD;
          -  Actual use of topical or systemic non-steroidal anti inflammatory agents&#xD;
&#xD;
          -  Actual or history of other macular diseases&#xD;
&#xD;
          -  Ocular surface diseases&#xD;
&#xD;
          -  Vitreomacular traction syndrome&#xD;
&#xD;
          -  Other vascular retinal diseases different to diabetic retinopathy&#xD;
&#xD;
          -  Actual or history of use of topical prostaglandin analogues&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dulce O Rascon-Vargas, Fellow</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación Para Evitar la Ceguera en México I.A.P.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guadalupe Cervantes-Coste</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación Para Evitar la Ceguera en México I.A.P.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jans Fromow-Guerra</last_name>
    <role>Study Director</role>
    <affiliation>Asociación Para Evitar la Ceguera en México I.A.P.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dulce O Rascon-Vargas, Fellow</last_name>
    <phone>(52) 55 10841400</phone>
    <phone_ext>1167</phone_ext>
    <email>dorv_md@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asociación Para Evitar la Ceguera en México I.A.P.</name>
      <address>
        <city>Mexico City</city>
        <zip>004030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dulce O Rascon-Vargas, Fellow</last_name>
      <phone>(52) 55 10841400</phone>
      <phone_ext>1167</phone_ext>
      <email>dorv_md@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asociacion para Evitar la Ceguera en Mexico I.A.P.</name>
      <address>
        <city>Mexico City</city>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guadalupe Cervantes-Coste</last_name>
      <phone>(52) 55 10841400</phone>
      <phone_ext>1167</phone_ext>
      <email>gpecervantes@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jans Fromow-Guerra</last_name>
      <phone>(52) 55 10841400</phone>
      <phone_ext>1167</phone_ext>
      <email>fromow@servidor.unam.mx</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>December 3, 2008</study_first_submitted>
  <study_first_submitted_qc>December 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2008</study_first_posted>
  <last_update_submitted>December 3, 2008</last_update_submitted>
  <last_update_submitted_qc>December 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dulce Oliva Rascon-Vargas</name_title>
    <organization>Asociación Para Evitar la Ceguera en México I.A.P.</organization>
  </responsible_party>
  <keyword>Macular thickening</keyword>
  <keyword>Macular edema</keyword>
  <keyword>Pan-retinal photocoagulation</keyword>
  <keyword>Nepafenac</keyword>
  <keyword>Topical non-steroidal anti inflammatory agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nepafenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

